ORIGINAL ARTICLE

PCGEM1 triggers liver cancer progression by positively regulating SNAI1

Yong Wang, Chen Chen, Xintian Wang, Chao Jiang

Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, China.

Summary

Purpose: To uncover the biological role of long non-coding RNA (lncRNA) PCGEM1 in regulating the progression of liver cancer and the molecular mechanism.

Methods: PCGEM1 levels in clinical specimens of liver cancer and cell lines were detected by quantitative real-time polymerase chain reaction (qRT-PCR). By analyzing the pathological data of recruited patients, the influences of PCGEM1 on tumor node metastasis (TNM) staging, tumor grading, lymphatic metastasis and overall survival of liver cancer patients were assessed. Hep3B and Huh7 cells were transfected with si-PCGEM1, followed by detection of proliferative, migratory and invasive rates through 5-Ethynyl-2'- deoxyuridine (EdU), cell counting kit-8 (CCK-8) and transwell assay. The interaction between PCGEM1 and SNAI1 was explored, and the biological functions of SNAI1 in liver cancer cell behaviors were finally detected.

Results: PCGEM1 and SNAI1 were upregulated in clinical specimens of liver cancer and cell lines. High level of PCGEM1 was detected in liver cancer cases with advanced staging, grading or lymphatic metastasis, which predicted poor prognosis of liver cancer patients. Knockdown of PCGEM1 reduced proliferative, migratory and invasive rates in Hep3B and Huh7 cells. SNAI1 was upregulated in liver cancer tissues and positively correlated to PCGEM1. Knockdown of SNAI1 also suppressed proliferative and metastatic potentials in Hep3B and Huh7 cells.

Conclusions: LncRNA PCGEM1 triggers liver cancer cells to proliferate, migrate and invade by upregulating SNAI1.

Key words: liver cancer, PCGEM1, SNAI1, proliferation, metastasis

Introduction

Liver cancer is prevalent throughout the world, and its mortality ranks second in malignant tumors. It is estimated that there are about 700,000 new cases of liver cancer each year in the world, and half of them are in China. The incidence and mortality of liver cancer in our country ranks third and second in global liver cancer cases, respectively [1,2]. It seriously affects health and lives of Chinese people. The occurrence and development of liver cancer are complex physiological processes, which are regulated by multiple factors and genes [3]. Lack of diagnostic and therapeutic targets for

early stage liver cancer results in the poor prognosis [4,5].

The human genome contains about 3 billion base pairs. Only fewer than 2% of them are able to encode proteins, and the vast majority are non-coding sequences [6]. Long non-coding RNAs (lncR-NAs) are non-coding RNAs exceed 200 nucleotides long, which are functional regulators involved in life activities. LncRNA HULC promotes adipogenesis and proliferation, and inhibits apoptosis of liver cancer cells. Besides, it enhances metastatic risk through strengthening EMT and downregulating

Corresponding author: Chao Jiang, MD. Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), 61 Jiefang West Road, Changsha, Hunan 410005, China. Tel: +860731-83928041, Email: 564878363@qq.com Received: 23/06/2020; Accepted: 12/08/2021 the anti-cancer gene CDKN2C [7,8]. It is indicated that HULC can be used as a potential diagnostic biomarker for liver cancer. LncRNA PTTG3P is upregulated in liver cancer cases, and it is positively correlated with the poor prognosis. PTTG3P drives liver cancer cells to proliferate, migrate and invade, while inhibits apoptosis through PTTG1-induced activation of the PI3K/AKT signaling [9]. Through literature review, lncRNAs are extensively involved in the physiological regulation of liver cancer.

LncRNA PCGEM1 was initially found to be overexpressed in human prostate cancer cells LN-CaP. PCGEM1 is involved in mediating invasive and proliferative potentials of prostate cancer [10]. PCGEM1 is detected to be highly expressed in colorectal carcinoma specimens than that of paracancerous ones [11]. In cancer tissues and serum samples of pancreatic cancer, PCGEM1 level increases, and its level is markedly enhanced during the differentiation of pancreatic cancer cells. Knockdown of PCGEM1 not only weakens proliferative ability of pancreatic cancer cells, but also downregulates proliferation-associated genes [12]. Our research group previously found that PCGEM1 is upregulated in liver cancer specimens. This study aims to explore the role of PCGEM1 in regulating the progression of liver cancer and the molecular mechanism.

Methods

Clinical specimens

Liver cancer (n=50) and adjacent non-tumoral tissues (n=50) were collected from liver cancer patients admitted in our hospital. Clinical specimens were pathologically confirmed, immediately frozen in liquid nitrogen and preserved at -80°C. Each patient was followed up after discharge. This study was approved by the research Ethics Committee of Hunan Provincial People's Hospital and complied with the Helsinki Declaration. Informed consent was obtained from patients.

Cell culture

Liver cancer cell lines (Hep3B, MHCC97-L, HC-CLM3, Huh7, Bel7402) and liver cell line (L02) were provided by the Institute of Hematology, Chinese Academy of traditional Chinese Medicine (Beijing, China). Cells were cultivated in Roswell Park Memorial Institute 1640 (RPMI 1640) (HyClone, South Logan, UT, USA) containing 10% fetal bovine serum (FBS) (HyClone, South Logan, UT, USA), 100 U/mL penicillin and 100 µg/mL streptomycin at 5%CO₃, 37°C.

Transfection

PCGEM1 siRNA, SNAI1 siRNA and negative control were provided by GenePharma (Shanghai, China). Briefly, cells were implanted in a 6-well plate with 5×10^5 cells/well. After cell density reached 80%, transfection was conducted using Lipofectamine[®] 2000 (Invitrogen, Carlsbad, CA, USA). Transfected cells were used for testing transfection efficacy at 24-48 h.

Quantitative real-time polymerase chain reaction (qRT-PCR)

Cells or tissues were lysed using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) for isolating RNAs. Qualified RNAs were reversely transcribed into complementary deoxyribose nucleic acids (cDNAs) using PrimeScript RT kit (Invitrogen, Carlsbad, CA, USA), followed by qRT-PCR using SYBR[®]Premix Ex Taq[™] (TaKaRa, Tokyo, Japan) at 92°C for 10 min, and 40 cycles at 92°C for 10 s and 60°C for 1 min. Glyceraldheyde 3-phosphate dehydrogenase (GAPDH) was served as the internal reference. Each sample was performed in triplicate, and relative level was calculated by $2^{-\Delta\Delta Ct}$. Primer sequences were as follows. PCGEM1 (F: 5'-CTGTGTCTGCAACTTC-CTCTAA-3', R: 5'-TCCCAGTGCATCTCGTAGTA-3'); SNAI1 (F: 5'-CCTTCGTCCTTCTCCTCTACTT-3', R: 5'-GGCACTG-GTACTTCTTGACATC-3'); GAPDH (F: 5'-GGAATCCACTG-GCGTCTTCA-3', R: 5'-GGTTCACGCCCATCACAAAC-3').

Cell counting kit-8 (CCK-8) assay

Cells were inoculated in a 96-well plate with 2×10^3 cells/well. At 0, 24, 48 and 72 h, optical density at 450 nm of each sample was recorded using the CCK-8 kit (Dojindo Laboratories, Kumamoto, Japan) for plotting the viability curves.

Transwell

Transwell chambers (8 µm; Millipore, Billerica, MA, USA) were inserted in each well of a 24-well plate, where 1×10^4 cells were applied in the upper layer of the chamber, and 600 µL of medium containing 10% FBS was applied in the bottom. After cell culture for 48 h, migratory cells to the bottom were captured following fixation and staining, which were counted in 5 randomly selected fields per sample (magnification 200×). Invasion assay was similarly conducted using Transwell chambers precoated with 200 mg/mL Matrigel.

5-Ethynyl-2'- deoxyuridine (EdU) assay

Cells were pre-inoculated in a 12-well plate with 5×10^4 cells/well. They were incubated in 4% methanol for 30 min, followed by 10-min permeabilization in 0.5% TritonX-100 (Solarbio, Beijing, China), and 30-min reaction in 400 µL of 1×ApollorR. Afterwards, cells were dyed in 4',6-diamidino-2-phenylindole (DAPI) for another 30 min in the dark. Positive EdU-stained cells were calculated.

Statistical analysis

Data processing was conducted using Statistical Product and Service Solutions (SPSS) 17.0 (SPSS Inc., Chicago, IL, USA). Figures were edited using Graph-Pad Prism (Version X; La Jolla, CA, USA). Two-paired independent t-test was performed for comparing differences between groups. Kaplan-Meier method was introduced for survival analysis. Correlation between PCGEM1 and SNAI1 levels in liver cancer tissues was assessed by Pearson correlation test. A significant difference was set at p<0.05.

Results

Clinical significance of PCGEM1 in liver cancer

QRT-PCR was conducted to detect differential level of PCGEM1 in clinical specimens of liver cancer and normal ones, and PCGEM1 was highly expressed in the former (Figure 1A). Subsequently, differential level of PCGEM1 in liver cancer tissues classified by tumor grading, TNM staging and lymphatic metastasis was examined. It is shown that PCGEM1 level remained higher in liver cancer cases with grading III, T3-T4 or accompanied



Figure 1. Clinical significance of PCGEM1 in liver cancer. **(A)** PCGEM1 was upregulated in liver cancer tissues than that of normal ones; **(B)** PCGEM1 level was linked to tumor grading of liver cancer; **(C)** PCGEM1 level was linked to tumor staging of liver cancer; **(D)** PCGEM1 level was linked to lymphatic metastasis of liver cancer. *p<0.05, **p<0.01.



Figure 2. Upregulation of PCGEM1 in liver cancer. **(A)** Prognostic value of PCGEM1 in liver cancer; **(B)** PCGEM1 was upregulated in liver cancer cells; **(C, D)** Transfection of si-PCGEM1 significantly downregulated PCGEM1 in Hep3B and Huh7 cells. *p<0.05, **p<0.01.



Figure 3. Knockdown of PCGEM1 reduced proliferative, migratory and invasive rates in liver cancer. **(A)** Transfection of si-PCGEM1 significantly decreased EdU-positive rate in Hep3B and Huh7 cells; **(B, C)** Transfection of si-PCGEM1 significantly decreased viability in Hep3B and Huh7 cells; **(D)** Transfection of si-PCGEM1 significantly suppressed migration in Hep3B and Huh7 cells; **(E)** Transfection of si-PCGEM1 significantly suppressed invasion in Hep3B and Huh7 cells. *p<0.05, **p<0.01.



Figure 4. PCGEM1 positively regulated SNAI1 expression. **(A)** SNAI1 was upregulated in liver cancer tissues than that of normal ones; **(B)** SNAI1 was positively correlated to PCGEM1 in liver cancer tissues; **(C, D)** Transfection of si-SNAI1 significantly downregulated SNAI1 in Hep3B and Huh7 cells; **(E)** Transfection of si-SNAI1 significantly downregulated PCGEM1 in Hep3B and Huh7 cells; **(F)** Transfection of si-PCGEM1 significantly downregulated SNAI1 in Hep3B and Huh7 cells; **(F)** Transfection of si-PCGEM1 significantly downregulated SNAI1 in Hep3B and Huh7 cells; **(F)** Transfection of si-PCGEM1 significantly downregulated SNAI1 in Hep3B and Huh7 cells. *p<0.05, **p<0.01.

lymphatic metastasis than those of controls (Figure 1B-D). Therefore, PCGEM1 was suggested to have a close relation to tumor grading, staging and lymphatic metastasis of liver cancer as a potential biomarker.

Upregulation of PCGEM1 in liver cancer

Through analyzing follow-up data of recruited liver cancer patients, it is found that upregulation of PCGEM1 predicted the worsening of overall survival in liver cancer (Figure 2A). Compared with normal liver cells, PCGEM1 was upregulated in liver cancer cells (Figure 2B). Hep3B and Huh7 cells were selected to generate *in vitro* knockdown model of PCGEM1 by transfection of si-PCGEM1 (Figure 2C, 2D).

Knockdown of PCGEM1 reduced proliferative, migratory and invasive rates in liver cancer

A series of functional experiments were carried out to explore the role of PCGEM1 in regulating liver cancer cells *in vitro*. Firstly, EdU assay showed a decline in EdU-positive rate after transfection of si-PCGEM1 in Hep3B and Huh7 cells (Figure 3A). Cell viability was also reduced in liver cancer cells with PCGEM1 knockdown (Figure 3B, 3C). Moreover, Transwell assay obtained the results that knockdown of PCGEM1 reduced migratory (Figure 3D) and invasive rates in liver cancer cells (Figure 3E).

PCGEM1 positively regulated SNAI1 expression

SNAI1 was detected to be highly expressed in liver cancer tissues than that of normal ones (Figure 4A). Its level was positively correlated to that of PCGEM1 in liver cancer (Figure 4B). Subsequently, we examined transfection efficacy of si-SNAI1 in Hep3B and Huh7 cells by qRT-PCR (Figure 4C, 4D). As expected, knockdown of SNAI1 downregulated PCGEM1 in liver cancer cells, and knockdown of PCGEM1 downregulated SNAI1 (Figure 4E, 4F).

Knockdown of SNAI1 reduced proliferative, migratory and invasive rates in liver cancer

We thereafter explored the biological function of SNAI1 in liver cancer cells. Both EdU and CCK-8 assay demonstrated that knockdown of SNAI1 attenuated proliferative capacity in Hep3B and Huh7 cells (Figure 5A-C). Besides, migratory and invasive capacities in liver cancer cells were suppressed by transfection of si-SNAI1 (Figure 5D-E).

Discussion

LncRNAs are becoming promising targets for tumor diagnosis, treatment and prognosis [13,14]. A growing number of lncRNAs have been identified in tumor profile, which are specifically expressed and provide novel ideas for developing diagnostic and therapeutic strategies [15,16]. Excessive prolif-



Figure 5. Knockdown of SNAI1 reduced proliferative, migratory and invasive rates in liver cancer. **(A)** Transfection of si-SNAI1 significantly decreased EdU-positive rate in Hep3B and Huh7 cells; **(B, C)** Transfection of si-SNAI1 significantly decreased viability in Hep3B and Huh7 cells; **(D)** Transfection of si-SNAI1 significantly suppressed migration in Hep3B and Huh7 cells; **(E)** Transfection of si-SNAI1 significantly suppressed invasion in Hep3B and Huh7 cells. *p<0.05, **p<0.01.

2408

eration of normal cells leads to carcinogenesis, that is, uncontrolled cell cycle progression. Abnormal division and proliferation that are not controlled by the normal growth system trigger the malignant transformation of normal cells to tumor ones [17,18]. Experimental data have verified that lncR-NAs are capable of regulating tumor development through mediating cell cycle progression. In the present study, lncRNA PCGEM1 was upregulated in clinical specimens of liver cancer and cell lines. High level of PCGEM1 was detected in liver cancer cases with advanced staging, grading or lymphatic metastasis, which predicted poor prognosis of liver cancer patients. In vitro experiments showed that knockdown of PCGEM1 reduced proliferative, migratory and invasive rates in Hep3B and Huh7 cells. It is concluded that PCGEM1 was an oncogene involved in liver cancer.

Drosophila embryonic protein SNAI1 is a zinc finger transcription factor gene that suppresses ectoderm and endoderm development. The nuclear protein encoded by SNAI1 is similar in structure to the Drosophila SNAI1 protein. SNAI1 is also considered to be the key gene to the formation of mesoderm during embryonic development [19]. SNAI1 participates in the negative expressions of EMT-associated transcription factors, which further inhibits tumor metastasis [20]. It is reported

that the positive expression of SNAI1 is detected in epithelial and endothelial cells of aggressive breast cancer, while it is not expressed in normal mammary glands [21]. SNAI1 is abundantly expressed in cadherin-negative clones of the epithelium of highly invasive oral squamous cell carcinoma (OSCC). However, it can be hardly detected in cadherinpositive clones of the epithelium of weakly invasive OSCC [22]. As a vital regulator of E-cadherin, SNAI1 is detected in colorectal adenoma, which is responsible for the downregulation of E-cadherin [23]. Our findings showed that SNAI1 was upregulated in liver cancer specimens, and displayed a positive correlation to PCGEM1. Knockdown of SNAI1 in Hep3B and Huh7 cells similarly weakened proliferative, migratory and invasive abilities. To sum up, PCGEM1 exerted its carcinogenic role in liver cancer by positively regulating SNAI1.

Conclusions

LncRNA PCGEM1 triggers liver cancer cells to proliferate, migrate and invade by upregulating SNAI1.

Conflict of interests

The authors declare no conflict of interests.

References

- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
- 2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76.
- 3. Xu R, Wang J, Huang X et al. Clinical value of spectral CT imaging combined with AFP in identifying liver cancer and hepatic focal nodular hyperplasia. J Buon 2019;24:1429-34.
- 4. Guttman M, Amit I, Garber M et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 2009;458:223-7.
- 5. Jarroux J, Morillon A, Pinskaya M. History, Discovery, and Classification of lncRNAs. Adv Exp Med Biol 2017;1008:1-46.
- 6. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell 2009;136:629-41.
- 7. Panzitt K, Tschernatsch MM, Guelly C et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 2007;132:330-42.
- 8. Xie H, Ma H, Zhou D. Plasma HULC as a promising

novel biomarker for the detection of hepatocellular carcinoma. Biomed Res Int 2013;2013:136106.

- 9. Huang JL, Cao SW, Ou QS et al. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma. Mol Cancer 2018;17:93.
- 10. Bastos V, Ferreira-de-Oliveira J, Carrola J et al. Coating independent cytotoxicity of citrate- and PEG-coated silver nanoparticles on a human hepatoma cell line. J Environ Sci (China) 2017;51:191-201.
- 11. Zhang S, Li Z, Zhang L, Xu Z. MEF2activated long noncoding RNA PCGEM1 promotes cell proliferation in hormonerefractory prostate cancer through downregulation of miR148a. Mol Med Rep 2018;18:202-8.
- 12. Chen S, Wang LL, Sun KX et al. LncRNA PCGEM1 Induces Ovarian Carcinoma Tumorigenesis and Progression Through RhoA Pathway. Cell Physiol Biochem 2018;47:1578-88.
- 13. Zhang Y, Zhang J, Liang S et al. Long non-coding RNA VIM-AS1 promotes prostate cancer growth and invasion by regulating epithelial-mesenchymal transition. J Buon 2019;24:2090-8.

- Rokavec M, Horst D, Hermeking H. Cellular Model of Colon Cancer Progression Reveals Signatures of mRNAs, miRNA, lncRNAs, and Epigenetic Modifications Associated with Metastasis. Cancer Res 2017;77:1854-67.
- 15. Huo X, Han S, Wu G et al. Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cells. Mol Cancer 2017;16:165.
- 16. Medinger M, Lengerke C, Passweg J. Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia. Cancer Genomics Proteomics 2016;13:317-29.
- 17. Li T, Xie J, Shen C et al. Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma. Oncogene 2016;35:1575-84.
- Spaderna S, Schmalhofer O, Hlubek F et al. A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 2006;131:830-40.

- 19. Paznekas WA, Okajima K, Schertzer M, Wood S, Jabs EW. Genomic organization, expression, and chromosome location of the human SNAIL gene (SNAI1) and a related processed pseudogene (SNAI1P). Genomics 1999;62:42-9.
- 20. Jouppila-Matto A, Narkio-Makela M, Soini Y et al. Twist and snail expression in pharyngeal squamous cell carcinoma stroma is related to cancer progression. Bmc Cancer 2011;11:350.
- 21. Parker BS, Argani P, Cook BP et al. Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res 2004;64:7857-66.
- 22. Yokoyama K, Kamata N, Hayashi E et al. Reverse correlation of E-cadherin and snail expression in oral squamous cell carcinoma cells in vitro. Oral Oncol 2001;37:65-71.
- 23. Kroepil F, Fluegen G, Totikov Z et al. Down-regulation of CDH1 is associated with expression of SNA11 in colorectal adenomas. Plos One 2012;7:e46665.